Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Deep brain stimulation is known to treat the symptoms of stiffness, slow movement, and tremor in people with Parkinson’s disease. Researchers are now a step closer to understanding exactly how this electrical stimulation of specific areas in the brain works.

Schematic illustration of ‘striatal damping’ by antidromic activation of striatopallidal axons. DA, dopaminergic; SNpc, substantia nigra pars compacta © James Fitzgerald
Schematic illustration of ‘striatal damping’ by antidromic activation of striatopallidal axons. DA, dopaminergic; SNpc, substantia nigra pars compacta

It is thought that part of the underlying problem for people with Parkinson’s is the overactivity of certain nerve cells. This overactivity affects the way that information flows from one circuit within the brain to another. In a paper published in the Journal of Neuroscience, researchers describe an experiment using deep brain stimulation that has demonstrated how the technique improves information flow between circuits, probably by calming down the overactive cells.

The researchers tested eye movements in 14 patients and 10 healthy controls. They electrically stimulated an area of the brain called the globus pallidus interna. They showed that this deep brain stimulation partially reverses deficits in voluntary control of eye movements, restoring some control.

This is an exciting finding because it suggests that deep brain stimulation might be able to address some of the non-motor aspects of Parkinson’s Disease
- Chrystalina Antoniades, lead author of the study.

The experiment showed improvement in information transfer between higher, cognitive, brain circuits and lower-level motor systems. This may mean that stimulation of the globus pallidus interna could have a positive effect on those symptoms of Parkinson’s disease that are not directly movement-related.

Read the paper online…

Read more about OcuLab…

Similar stories

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Dr Ruxandra Dafinca awarded an Alzheimer’s Society Dementia Research Leader Fellowship

Ruxandra Dafinca is one of 17 early career researchers awarded a fellowship in the 2025/2026 call for her project focused on frontotemporal dementia.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease

Oxford researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.

Collaboration with the Nepal Public Health Foundation (NPHF) explores maternal health and epilepsy

A new study, co-led by Professor Arjune Sen and supported by Nuffield Department of Clinical Neurosciences, aims to improve understanding of the risk factors, care pathways and broader health and social impacts of epilepsy in Nepal.